www.faruqilaw.com/BLCM. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 489168

"/> BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm « MarketersMedia – Press Release Distribution Services – News Release Distribution Services
Great News! MarketersMedia is officially entering into a long-term partnership with Vertical News Network.
Learn More
How It Works? Plans & Pricing Our Distributions Newsroom Info Hub Sign Up Sign In Send Press Release Contact Sales
Contact Sales Sign Up Your Account Send Press Release
MarketersMEDIA / Newsroom / BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm

BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm

Share This Press Release

NEW YORK, NY / ACCESSWIRE / February 13, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bellicum Pharmaceuticals, Inc. (''Bellicum'' or the ''Company'') (NASDAQ: BLCM).

Aftermarket on January 30, 2018, Bellicum issued a press release entitled ''Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States[.]'' Therein, the Company announced that it had ''received notice from the U.S. Food and Drug Administration (FDA) that U.S. studies of BPX-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.'' BPX-501 is the Company's lead clinical product candidate designed to improve outcomes for patients undergoing stem cell transplant who lack a matched donor.

On this news, the Company's share price fell from $8.20 per share on January 30, 2018 to a closing price of $6.08 on January 31, 2018 - a $2.12 or a 25.85% drop.

If you invested in Bellicum stock or options and would like to discuss your legal rights, click here:
www.faruqilaw.com/BLCM. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to
rgonnello@faruqilaw.com.

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 489168

NEW YORK, NY / ACCESSWIRE / February 13, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bellicum Pharmaceuticals, Inc. (''Bellicum'' or the ''Company'') (NASDAQ: BLCM).

Aftermarket on January 30, 2018, Bellicum issued a press release entitled ''Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States[.]'' Therein, the Company announced that it had ''received notice from the U.S. Food and Drug Administration (FDA) that U.S. studies of BPX-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.'' BPX-501 is the Company's lead clinical product candidate designed to improve outcomes for patients undergoing stem cell transplant who lack a matched donor.

On this news, the Company's share price fell from $8.20 per share on January 30, 2018 to a closing price of $6.08 on January 31, 2018 - a $2.12 or a 25.85% drop.

If you invested in Bellicum stock or options and would like to discuss your legal rights, click here:
www.faruqilaw.com/BLCM. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to
rgonnello@faruqilaw.com.

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 489168

Source URL: https://marketersmedia.com/bellicum-investor-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exceeding-50000-investing-in-bellicum-pharmaceuticals-inc-to-contact-the-firm/300558

Source: AccessWire

Release ID: 300558

Latest Releases


Fatal error: Call to undefined function related_posts() in /home/marketer/public_html/wp-content/themes/mm/single-content.php on line 211